INTRODUCTION

The frequency of upper urinary tract urothelial carcinoma (UTUC) is approximately 5% of urothelial malignancies and <10% of renal tumors [1]. This cancer can be treated by radical nephroureterectomy with excision of the bladder cuff, but treatment is often problematic owing to difficulties in early diagnosis, the high incidence of tumor recurrence, and poor prognostic outcomes [2]. Because systemic recurrences are common in this disease, it is reasonable to consider perioperative treatments that might reduce this risk. However, few studies have explored...
such perioperative treatments, including chemotherapy or radiation therapy, and these limited studies have yielded conflicting results.

Some potential perioperative agents that might confer chemoprotective effects are vitamin A, vitamin E, vitamin C, selenium, nonsteroidal anti-inflammatory drugs, isoflavone, and statins (hydroxymethylglutaryl-CoA-reductase inhibitors). Of these, statins have been used to treat high cholesterol in general owing to their efficacy and minimal side effects. Statins improve the blood lipid profile, treat a number of cardiovascular diseases, and specifically reduce mortality from coronary heart disease [3]. Although vascular secondary end points are the main clinical target of these agents, statins also affect other conditions. In particular, a growing body of evidence suggests that statins provide a chemoprotective advantage against many cancers [4,5], likely by arresting cell cycle progression, suppressing angiogenesis, inducing apoptosis, and inhibiting tumor growth and metastasis [6-8].

Currently, preclinical data show that statins induce cell cycle arrest and apoptosis and inhibit proliferation in human urothelial carcinoma cell lines [9]. Thus, statins may have an antineoplastic effect on urothelial carcinoma. However, the impact of statin use has been investigated mainly in patients with lower urinary tract carcinomas owing to the infrequency of UTUC. In previous studies, statin use showed conflicting effects on the prognosis of patients with lower UTUC [10-12], and only one multi-institutional study did not suggest an influence of statin therapy on UTUC prognosis [13]. However, these studies were limited by heterogeneous groups of patients and variable follow-up schedules according to each institution. Therefore, we assessed the impact of statins on oncologic outcomes in patients with UTUC after radical nephroureterectomy performed at a single center.

MATERIALS AND METHODS

1. Study population and data collection

The study protocol was approved by the Institutional Review Board. A review of the medical records of our single institute identified 291 patients with primary UTUC who underwent radical nephroureterectomy between January 2006 and December 2011. Patients who had previous or synchronous invasive bladder cancer, who had distant metastasis at diagnosis, or who had received neoadjuvant therapy were excluded. Three patients with concomitant invasive bladder cancer and 11 patients with distant metastasis at diagnosis were excluded from analysis. The study cohort consisted of 277 consecutive patients.

Each patient underwent a preoperative evaluation, which included blood tests, urine cytology, cystoscopy, chest x-ray, abdominopelvic computerized tomography, and a bone scan. Information regarding medication use (statin use), the presence of comorbid illnesses, smoking history, and alcohol intake history was obtained from the electronic database. Because of the retrospective nature of data collection, we were unable to obtain the duration of statin use because this information was not available in the charts. The anesthesiologists used the American Society of Anesthesiologists score prior to surgery to assess the ability of patients to undergo surgery [14].

2. Pathological evaluation

In all cases, surgery was performed with curative intent. Radical nephroureterectomy with bladder cuff excision was performed and lymphadenectomy was performed when enlarged lymph nodes were either identified on preoperative computed tomography or were palpable during surgery. Dissection of the regional lymph nodes was performed in 101 patients (36.5%). Tumors were pathologically staged by using the 2010 American Joint Committee on Cancer TNM staging system, and tumors were graded according to the 2004 World Health Organization classification [15,16]. Lymphovascular invasion was defined as the presence of tumor cells within an endothelium-lined space without underlying muscular walls [17]. Adjuvant therapy was selectively recommended for patients with locally advanced or node-positive disease on pathology, except for those who could not tolerate chemotherapy of refused treatment. Adjuvant therapy was administered to 42 patients (12.3%), including 31 who received adjuvant chemotherapy and 27 who received adjuvant radiation therapy.

3. Follow-up

Follow-up consisted of chest radiography and abdominopelvic computed tomography every 6 months for the first 2 years and annually thereafter. Surveillance cystoscopy was generally performed every 3 months for the first 2 years after radical nephroureterectomy, every 6 months for the next 2 years, and annually thereafter. Tumor recurrence was defined as local failure in the tumor bed or regional lymph nodes or distant metastasis. Since bladder recurrence did not affect survival in the current patient population, this factor was not considered when calculating the RFS rate. The cause of death was determined by chart review and was corroborated by death certificates. All patients who died of cancer also had previous disease recurrence.
4. Statistical analysis

The statin user and nonuser subgroups were compared in terms of clinicopathological factors by using Pearson chi-square test or Fisher exact test for categorical variables and Student t-test or Mann Whitney U-test for continuous variables. Kaplan-Meier survival curves were used to estimate RFS and CSS and were compared by using the log-rank test. A Cox proportional hazards regression model was used to estimate the prognostic significance of each variable. Correlations between outcomes and variables were expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). All statistical tests were two-tailed, with p<0.05 considered to be significant. All statistical analyses were performed by using the IBM SPSS Statistics ver. 21.0 (IBM Co., Armonk, NY, USA).

RESULTS

1. Baseline characteristics of the statin user and nonuser groups

Of the 277 patients, 62 (22.4%) reported being on statins at the time of radical nephroureterectomy, whereas 215

Table 1. Baseline clinicopathologic characteristics of patients in the statin use and nonuse groups

| Variable                  | Statin user (n=62) | Statin nonuser (n=215) | p-value |
|---------------------------|-------------------|------------------------|---------|
| Age (y)                   | 66.8±8.8          | 62.7±10.4              | 0.006   |
| Body mass index (kg/m²)   | 25.6±3.7          | 24.5±3.2               | 0.015   |
| Gender                    | 0.738             |                        |         |
|   Male                    | 46 (74.2)         | 164 (76.3)             |         |
|   Female                  | 16 (25.8)         | 51 (23.7)              |         |
| Cardiovascular disease    | 17 (27.4)         | 33 (15.3)              | 0.039   |
| Hypertension              | 31 (50.0)         | 83 (38.6)              | 0.143   |
| Diabetes                  | 20 (32.3)         | 32 (14.9)              | 0.003   |
| ASA scores                | 0.190             |                        |         |
|   1                       | 5 (8.1)           | 24 (11.2)              |         |
|   2                       | 56 (90.3)         | 184 (85.6)             |         |
|   3                       | 1 (1.6)           | 7 (3.2)                |         |
| Smoking history           | 0.660             |                        |         |
|   Current smoker          | 6 (9.7)           | 28 (13.0)              |         |
|   Nonsmoker               | 56 (90.3)         | 187 (87.0)             |         |
| Bladder cancer history    | 1.000             |                        |         |
|   Yes                     | 11 (17.7)         | 37 (17.2)              |         |
|   No                      | 51 (82.3)         | 178 (82.8)             |         |
| Tumor location            | 1.000             |                        |         |
|   Renal pelvis            | 26 (41.9)         | 89 (41.4)              |         |
|   Ureter                  | 36 (58.1)         | 126 (58.6)             |         |
| Pathologic T stage        | 0.284             |                        |         |
|   ≤T1                     | 25 (40.3)         | 100 (46.5)             |         |
|   T2                      | 9 (14.6)          | 38 (17.7)              |         |
|   T3                      | 25 (40.3)         | 74 (34.4)              |         |
|   T4                      | 3 (4.8)           | 3 (1.4)                |         |
| Pathologic grade          | 0.473             |                        |         |
|   Low                     | 25 (40.3)         | 98 (45.6)              |         |
|   High                    | 37 (59.7)         | 117 (54.4)             |         |
| Lymph node status         | 1.000             |                        |         |
|   N0 or Nx                | 57 (91.9)         | 197 (91.6)             |         |
|   N1-3                    | 5 (8.1)           | 18 (8.4)               |         |
| Lymphovascular invasion   | 23 (37.1)         | 55 (25.6)              | 0.080   |
| Positive surgical margin  | 5 (7.9)           | 17 (7.9)               | 1.000   |
| Adjuvant therapy          | 14 (22.6)         | 28 (13.0)              | 0.072   |

Values are presented as mean±standard deviation or number (%).
ASA, American Society of Anesthesiologists.
Impact of statin use on urothelial carcinoma were not. The statins used were lipophilic (n=57, 91.9%) and hydrophilic (n=5, 8.1%). The baseline clinicopathological characteristics of the patients are shown in Table 1. The two groups differed significantly in terms of age, body mass index (BMI), cardiovascular disease, and diabetes status. Compared to the statin nonusers, the statin users were older (66.8±8.8 years vs. 62.7±10.4 years, p=0.006), had higher BMIs (25.6±3.7 kg/m² vs. 24.5±3.2 kg/m², p=0.015), and had higher rates of cardiovascular disease (27.4% vs. 15.3%, p=0.039) and diabetes (32.3% vs. 14.9%, p=0.003). There were no significant differences in tumor stage, grade, lymphovascular disease, surgical margin status, or adjuvant therapy rate between the two groups.

2. Impact of statin use on cancer recurrence and mortality

At a median follow-up time of 40 months, 58 patients (18.8%) had disease recurrence and 42 patients (15.2%) had already died from UTUC progression. Of the patients who had died, 7 (11.3%) were statin users and 35 (16.3%) were statin nonusers. The 5-year RFS rates of statin users and nonusers were 78.5% and 72.5%, respectively (p=0.528) (Fig. 1A), and the 5-year CSS rates were 85.6% and 77.7%, respectively (p=0.516) (Fig. 1B). The 5-year OS rates were 74.3% and 71.4%, respectively (p=0.945) (Fig. 1C). Limiting the analysis to lipophilic statin agents only (i.e., rosuvastatin was excluded) also had no significant effect on outcomes (data not shown).

Table 2 presents the results of the univariate and multivariate analyses of RFS and CSS. Multivariate analysis revealed that the only statistically significant predictors of RFS and CSS were tumor grade, tumor stage, and adjuvant therapy. However, statin use (HR, 0.47; 95% CI, 0.22–1.02; p=0.056) was not an independent prognostic factor for RFS (HR, 0.47; 95% CI, 0.22–1.02; p=0.056) and CSS (HR, 0.46; 95% CI, 0.18–1.14; p=0.093).

In the multivariate analysis of prognostic factors for OS (data not shown), age (HR, 1.05; 95% CI, 1.02–1.07; p<0.001), tumor grade (HR, 1.97; 95% CI, 1.21–3.23; p=0.008), tumor stage (HR, 2.03; 95% CI, 1.20–3.42; p=0.001), surgical margin (HR, 212; 95% CI, 116–386; p=0.0014), and lymph node status (HR, 2.39; 95% CI, 1.34–4.26; p=0.003) were independent

---

**Fig. 1.** (A) Recurrence-free survival in statin users and nonusers. (B) Cancer-specific survival in statin users and nonusers. (C) Overall survival in statin users and nonusers.
prognostic factors for OS in patients who underwent radical nephroureterectomy for UTUC.

**DISCUSSION**

Currently, statins are being researched in a number of studies for their ability to prevent a variety of cancers, but the results have been inconsistent. One recent study showed that cancer patients who used statins prior to diagnosis had reduced CSS compared with that of patients who had never taken statins [5]. However, that study did not report on UTUC patients specifically and the effects of statin use on the clinical treatment outcomes of urothelial cell carcinoma are unknown.

Especially in urology, the effect of statins on prostate cancer incidence and disease progression has been investigated in many studies [18,19]. Recent meta-analysis showed a 33% risk reduction for advanced high-grade or metastatic prostate cancer [20] and that statin use protects against prostate cancer with poorer pathological characteristics [21]. In our previous study [22], we showed that postoperative statin use decreased the risk of biochemical recurrence, especially in patients with high-risk disease. However, only few studies have investigated the effect of statins on urothelial carcinoma incidence and prognosis. In one previous study that examined the effects of atorvastatin on human bladder cancer cell lines, a significant anti-proliferative effect was observed in the statin group compared with controls [9]. In another study using mouse cells transfected with the H-ras oncogene from human bladder carcinoma, the researchers observed that statin treatment significantly inhibited Ras oncogene-transformed cells [23]. Thus, statin may have an antineoplastic effect on urothelial carcinoma. However, these studies are preclinical data.

To date, only a few studies have focused their investi-

---

**Table 2. Univariate and multivariate analysis of prognostic factors for recurrence (except bladder recurrence) and cancer-specific survival**

| Variable     | Recurrence-free survival | Cancer-specific survival |
|--------------|--------------------------|-------------------------|
|              | Univariate               | Multivariate            | Univariate | Multivariate |
|              | Hazard ratio (95% CI)    | p-value                 | Hazard ratio (95% CI) | p-value |
|              |                          |                         | Hazard ratio (95% CI) | p-value |
| Age          | 1.12 (0.98–1.04)         | 0.434                   | 1.02 (0.98–1.05)     | 0.335   |
| Body mass index | 0.96 (0.88–1.05)       | 0.397                   | 0.98 (0.89–1.08)     | 0.715   |
| Statin use  |
| No          | 1                        | 1                       | 1                        | 1               |
| Yes         | 0.95 (0.45–1.97)         | 0.886                   | 0.47 (0.22–1.02)       | 0.056   |
| Tumor location |
| Pelvis      | 1                       | 1                       | 1                        | 1               |
| Ureter      | 1.33 (0.73–2.41)         | 0.348                   | -                        | -               |
| Tumor grade |
| Low         | 1                       | 1                       | 1                        | 1               |
| High        | 6.25 (2.64–14.80)        | <0.001                  | 3.79 (1.53–9.35)       | 0.004   |
| Tumor stage |
| ≤T2         | 1                       | 1                       | 1                        | 1               |
| ≥T3         | 5.67 (2.39–13.43)        | <0.001                  | 3.31 (1.57–6.96)       | 0.002   |
| Node status |
| pN0 or pNx  | 1                       | 1                       | 1                        | 1               |
| pN1-3       | 2.72 (1.21–6.10)         | 0.016                   | 1.31 (0.55–3.11)       | 0.540   |
| LVI          |
| No          | 1                       | 1                       | 1                        | 1               |
| Yes         | 2.57 (1.42–4.67)         | 0.002                   | 1.28 (0.67–2.45)       | 0.459   |
| Surgical margin |
| Negative   | 1                       | 1                       | 1                        | 1               |
| Positive   | 3.58 (1.51–8.51)         | 0.004                   | 1.87 (0.76–4.58)       | 0.172   |
| Adjuvant therapy |
| No         | 1                       | 1                       | 1                        | 1               |
| Yes        | 5.36 (2.89–9.95)         | <0.001                  | 2.39 (1.19–4.80)       | 0.015   |

Cl, confidence interval; LVI, lymphovascular invasion.
gations on the clinical effect of statins on urothelial carcinoma incidence and prognosis, and these studies have primarily concentrated on bladder carcinoma, not UTUC. Tsai et al. [12] suggested that statins may improve local control in patients who underwent concurrent chemoradiotherapy for muscle-invasive bladder cancer. However, this study showed that statin use was associated with local control only in univariate, not multivariate, analysis. Recently, one multi-institutional study found that statin use was not associated with RFS or CSS in patients treated with radical cystectomy for bladder cancer. Similarly, statin use was also not associated with RFS or CSS in patients treated with radical cystectomy for bladder cancer, and statins did not affect the oncologic outcome for non–muscle-invasive bladder cancer [10,11]. Additionally, a recent meta-analysis study showed no significant association between statin use and the risk of bladder cancer [24]. Furthermore, there have been 5 retrospective studies exploring the impact of statin use on patient responses to Bacillus Calmette-Guerin (BCG) immunotherapy. Hoffmann et al. [25] reported that concurrent statin therapy with BCG might reduce the clinical efficacy of BCG therapy. Statin users were more likely to proceed to more aggressive disease as well as to require radical cystectomy. However, subsequent studies failed to confirm that statin therapy affects patient responses to BCG [11,26-28]. These studies found no differences between statin users and nonusers in the mean number of recurrences or incidence of disease progression, CSS, or OS. Overall, these results are consistent with the findings in our study, in which statin use did not improve RFS, CSS, or OS after radical nephroureterectomy for UTUC.

When interpreting our data, several noteworthy limitations should be considered. First, because the findings represent the clinical experience of a single center, the rate of patients taking statins was lower than in a previous study [13]. However, the prevalence of statin use in patients 50 years or older was 22.8% in 2008 [29]. Second, medical chart review can be an unreliable method for determining the duration and dosage of medications used by a study population, because much of this information may not be reported consistently in the medical records. It would be interesting to assess the correlation between the dosage and duration of statin use with prognosis, but unfortunately, this information was not available in the patient records. Therefore, well-designed, prospective, randomized trials that include a large patient population are warranted. Despite the limitations of the present study, to the best of our knowledge, this is the first single-center study to investigate the potential impact of statin use on the clinical outcomes of patients with UTUC being treated with radical nephroureterectomy.

CONCLUSIONS

In patients undergoing radical nephroureterectomy for UTUC, statin use was not associated with RFS, CSS, or OS. Owing to the inherent limitations of this retrospective study, the potential antineoplastic effect of statins needs further investigation prospectively.

CONFLICTS OF INTEREST

The authors have nothing to disclosure.

REFERENCES

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998;52:594-601.
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
4. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007;120:833-43.
5. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-802.
6. Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 2005;5:579-94.
7. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-87.
8. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-19.
9. Kamat AM, Nelkin GM. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 2005;66:1209-12.
10. da Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, et al. Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol 2013;190:487-92.
11. Crivelli JJ, Xylinas E, Kluth LA, da Silva RD, Chrystal J, Novara G, et al. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU Int 2013;112:E4-12.
12. Tsai HK, Katz MS, Coen JJ, Zietman AL, Kaufman DS, Shipley WU. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer. Urology 2006;68:1188-92.
13. Xylinas E, Kluth LA, Crivelli JJ, Rieken M, Margulis V, Seitz C, et al. Impact of statin use on oncologic outcomes of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. Eur Urol 2013;63:1134-5.
14. Owens WD, Felts JA, Spitznagel EL Jr. ASA physical status classifications: a study of consistency of ratings. Anesthesiology 1978;49:239-43.
15. May M, Brookman-Amissah S, Roigas J, Hartmann A, Storkel S, Kristiansen G, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 2010;57:850-8.
16. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-4.
17. Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 2010;57:1064-71.
18. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, et al. Statin use and risk of prostate cancer in the California Men’s Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2218-25.
19. Platz EA, Leitzmann MF, Viswanathan K, Rimm EB, Stampfer MJ, Willett WC, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-25.
20. Bonovas S, Filoussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008;123:899-904.
21. Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol 2011;185:1268-73.
22. Song C, Park S, Park J, Shim M, Kim A, Jeong IG, et al. Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer. Prostate 2015;75:211-7.
23. Sebti SM, Tkalcevic GT, Jani JP. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun 1991;3:141-7.
24. Zhang XL, Geng J, Zhang XP, Peng B, Che JP, Yan Y, et al. Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes Control 2013;24:769-76.
25. Hoffmann P, Roumeguère T, Schulman C, van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 2006;355:2705-7.
26. Kamat AM, Wu X. Statins and the effect of BCG on bladder cancer. N Engl J Med 2007;356:1276.
27. Skolarus TA, Lee EW, Virgo KS, Katz MD, Hudson MA, Kibel AS, et al. Intravesical bacille Calmette-Guérin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy. J Am Coll Surg 2009;209:248-53.
28. Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. J Urol 2008;180:1297-300.
29. Geleedst-De Vooght M, Maitland-van der Zee AH, Schalekamp T, Mantel-Teeuwisse A, Jansen P. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study. Drugs Aging 2010;27:589-96.